First Manhattan’s Accelerate Diagnostics AXDX Stock Holding History

First Manhattan’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$45K	–	1358
2018 Q3	$45K	Hold	200	–	–	﹤0.01%	997
2018 Q2	$44K	Hold	200	–	–	﹤0.01%	975
2018 Q1	$45K	Hold	200	–	–	﹤0.01%	972
2017 Q4	$52K	Buy	+200	New	+$46.9K	﹤0.01%	994
2016 Q4	–	Sell	-475	Closed	-$129K	–	1370
2016 Q3	$129K	Hold	475	–	–	﹤0.01%	754
2016 Q2	$68K	Hold	475	–	–	﹤0.01%	887
2016 Q1	$68K	Hold	475	–	–	﹤0.01%	861
2015 Q4	$102K	Hold	475	–	–	﹤0.01%	810
2015 Q3	$76K	Hold	475	–	–	﹤0.01%	856
2015 Q2	$122K	Sell	475 -120	-20%	-$28.7K	﹤0.01%	784
2015 Q1	$133K	Buy	595 +120	+25%	+$25.1K	﹤0.01%	773
2014 Q4	$91K	Hold	475	–	–	﹤0.01%	855
2014 Q3	$102K	Sell	475 -475	-50%	-$92.4K	﹤0.01%	814
2014 Q2	$247K	Buy	+950	New	+$207K	﹤0.01%	650

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

CAM

Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

First Manhattan's AXDX Position: Q4 2018 in Review

First Manhattan sold out of Accelerate Diagnostics (AXDX) in Q4 2018, closing a stake of 200 shares — an estimated $45K sold.

First Manhattan first reported a position in AXDX in Q2 2014 and held it in 14 quarters. The position peaked at $247K in Q2 2014. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2018.

First Manhattan reported no remaining Accelerate Diagnostics position as of Q4 2018 after selling out during the quarter.
First Manhattan sold 200 Accelerate Diagnostics shares in Q4 2018, an estimated $45K.
First Manhattan first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 14 quarters.
First Manhattan's Accelerate Diagnostics position peaked at $247K in Q2 2014.
107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2018.

Based on First Manhattan's 13F filing for Q4 2018, filed 30 Jan 2019.